Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib + Exemestane in ER+ Advanced Breast Cancer
NCT01594216Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Apr 2012
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruxolitinib in breast cancer (2 arms), sponsored by Abramson Cancer Center. Primary endpoints: Number of Participants With Adverse Events at 3 years and Time to Progression at 3 years. Started Apr 2012; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01594216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01594216.